Sage Journals: Discover world-class research

Abstract

Two methods were used to estimate the long-term impact of disease-modifying drug therapy (DMDT) in patients with relapsing multiple sclerosis (MS) who completed a placebo-controlled, randomized clinical trial of interferon beta-1a (IFNβ-1a). The study cohort consisted of patients with ambulatory relapsing MS who had previously participated in a placebo-controlled clinical trial for two years. At its end, patients were managed in an unstructured fashion by their neurologists and re-evaluated at an average of 6.1 years after the end of the trial. Follow-up evaluation was obtained for 93% of the 172 eligible patients. Because study inclusion criteria required that all patients have an Expanded Disability Status Scale (EDSS) score of ≤3.5 at entry, disability progression at follow-up was defined as EDSS≥6.0. Two methods were used to estimate the expected proportions that reached EDSS≥6.0 at follow-up. Estimates were compared with observed proportions. Method 1 used progression rates observed during the two-year phase III clinical trial and the percentage of time that patients were on DMDT during the follow-up period. Method 2 used progression rates from a natural history comparison group of relapsing-remitting MS patients. At the eight-year follow-up, 42.0% of the original placebo patients and 29.1% of the original IFNβ-1a patients reached an EDSS ≥ 6.0, an observed treatment effect of approximately 30%. Using method 1, it was estimated that 36.3% of the original placebo patients and 27.6% of the original IFNβ-1a patients should have reached an EDSS ≥ 6.0. Use of the natural history control group (method 2) predicted less plausible outcomes. Estimated proportions of patients reaching the endpoint were 63.3% for the original placebo group and 55.8% for the original IFNβ-1a group. Treatment effect sizes of 75-90% would be required to match estimates from method 2 with the observed outcome. The paucity of data on the long-term treatment of patients with MS may be aided by applying these or similar methods to vigorously followed cohorts of patients.

Keywords

disease-modifying drug therapy interferon beta multiple sclerosis

Get full access to this article

View all access options for this article.

References

The IFNβ Multiple Sclerosis Study Group . Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial . Neurology 1993; 43: 655-661 .

Jacobs LD , Cookfair DL , Rudick RA , Herndon RM , Richert JR , Salazar AM et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis . Ann Neurol 1996; 39: 285-294 .

PRISMS (Prevention of Relapses and Disability by Interferon b-1a Subcutaneously in Multiple Sclerosis) Study Group . Randomised double-blind placebo-controlled study of inter-feron b-1a in relapsing/remitting multiple sclerosis . Lancet 1998; 352: 1498-1504 .

Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) . Neurology 1983; 33: 1444-1452 .

Lublin FD , Reingold SC , and the National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS. Placebo-controlled clinical trials in multiple sclerosis: ethical considerations . Ann Neurol 2001; 49: 677-681 .

Schwid SR , Bever CT Jr. The cost of delaying treatment in multiple sclerosis. What is lost is not regained . Neurology 2001; 56: 1620-1620 .

The PRISMS (Prevention of Relapses and Disability by Inter-feron-b-1a Subcutaneously in Multiple Sclerosis) Study Group , and the University of British Columbia MS/MRI Analysis Group . PRISMS-4: long-term efficacy of interferon-b-1a in relapsing MS . Neurology 2001; 56: 1628-1636 .

Herndon RM , Jacobs LD , Coats ME , Goodkin DE , Mass MK , Richert JR et al. Results of an ongoing, open-label, safety-extension study of interferon beta-1a (Avonex) treatment in multiple sclerosis . Int J MS Care [serial online] 1999; 1: 1-6 . Retrieved 5 May, 2003, from http://www.mscare.com

Weinshenker BG , Bass B , Rice GPA , Noseworthy J , Carriere W , Baskerville J , Ebers GC. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability . Brain 1989; 112: 133-146 .

10.

Fisher E , Rudick RA , Cutter G , Baier M , Miller D , Weinstock-Guttman B et al. Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients . Mult Scler 2000; 6: 373-377 .

11.

Fisher E , Rudick RA , Simon JH , Cutter G , Baier M , Lee J-C et al. Eight-year follow-up study of brain atrophy in patients with MS . Neurology 2002; 59: 1412-1420 .

12.

Miller DM , Rudick RA , Baier M , Cutter G , Dougherty DS , Weinstock-Guttman B et al. Factors that predict health-related quality of life in patients with relapsing-remitting multiple sclerosis . Mult Scler 2003; 9: 1-5 .

13.

Rudick RA , Cutter G , Baier M , Fisher E , Dougherty D , Wein-stock-Guttman B et al. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS . Neurology 2001; 56: 1324-1330 .

14.

Rudick RA , Fisher E , Lee JC , Duda JT , Simon J. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon b-1a . Mult Scler 2000; 6: 365-372 .

15.

Rudick R , Antel J , Confavreux C , Cutter G , Ellison G , Fischer J et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force . Ann Neurol 1997; 42: 379-382 .

16.

Bergner M , Bobbitt RA , Kressel S , Pollard WE , Gilson BS , Morris JR. The sickness impact profile: conceptual formulation and methodology for the development of a health status measure . Int J Health Serv 1976; 6: 393-415 .

17.

John Hopkins University . The Sickness Impact Profile User’s Manual and Interpretation Guide. Baltimore, MD: Johns Hopkins University, Department of Health Policy and Management , 1996.

18.

Ratzker PK , Feldman JM , Scheinberg LC , Larocca NG , Smith CR , Giesser BS , Aisen ML. Self-assessment of neurologic impairment in multiple sclerosis . J Neurol Rehab 1997; 11: 207-211 .

19.

Johnson KP , Brooks BR , Cohen JA , Ford CC , Goldstein J , Lisak RP et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial . Neurology 1995; 45: 1268-1276 .

20.

Johnson KP , Brooks BR , Ford CC , Goodman A , Guarnaccia J , Lisak RP et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years . Mult Scler 2000; 6: 255-266 .

Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients

Abstract

Keywords

Get full access to this article

References